Oncology Success Rates Webinar Recording

Read also

• In Vivo: strategic insights for life sciences decision-maker...

  A Tale Of Two Pipelines

  Immuno-oncology has produced some exciting successes, but the field has become intensely crowded. Enormous resources are being poured into duplicative work and shaky hypotheses—overshadowing other pursuits in cancer research while producing limited results. It is time to re-evaluate how the sector should be pursuing innovation in cancer and how it can be smarter in its use of resources—financial investment, talent, bandwidth, patients and data.

  Topics Cancer Research

  View Analysis

• Citeline

  Breast Cancer Clinical Landscape and Recent Trends Whitepaper

  Get a deeper understanding of breast cancer clinical trials initiated since 2014 and what the trends have meant for strategies in this area, with this free whitepaper from Citeline.

  Topics Cancer Clinical Trials Research

  View white paper

• Pink Sheet: global policy and regulatory coverage

  US FDA Approval Of Lynparza For Pancreatic Cancer Opens Door For PFS Endpoint In Disease

  By Michael Cipriano

  AstraZeneca's PARP inhibitor Lynparza becomes first US FDA-approved drug for pancreatic cancer based on progression-free survival endpoint, providing regulatory precedent for other sponsors to use that development approach; all other pancreatic cancer drugs had been approved based on an overall survival benefit.

  Topics Cancer Clinical Trials

  View Analysis